Enovis (NYSE:ENOV) Insider Purchases $24,770.00 in Stock

Enovis Corporation (NYSE:ENOV) insider Oliver Engert bought 1,000 shares of the stock in a transaction that occurred on Tuesday, March 3rd. The stock was bought at an average cost of $24.77 per share, for a total transaction of $24,770.00. Following the completion of the purchase, the insider directly owned 44,640 shares of the company’s stock, valued at $1,105,732.80. This represents a 2.29% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Oliver Engert also recently made the following trade(s):

• On Wednesday, March 4th, Oliver Engert purchased 250 shares of Enovis stock. The stock was bought at an average cost of $25.10 per share, with a total value of $6,275.00.
• On Friday, February 27th, Oliver Engert purchased 1,000 shares of Enovis stock. The stock was bought at an average cost of $25.50 per share, for a total transaction of $25,500.00.

Enovis Stock Performance

Enovis stock opened at $24.49 on Friday. Enovis Corporation has a fifty-two week low of $21.00 and a fifty-two week high of $40.69. The company has a debt-to-equity ratio of 0.85, a quick ratio of 1.04 and a current ratio of 2.02. The stock has a market cap of $1.40 billion, a P/E ratio of -1.18 and a beta of 1.46. The firm’s fifty day moving average price is $24.10 and its 200-day moving average price is $28.03.

Enovis (NYSE:ENOV) last announced its earnings results on Thursday, February 26th. The company reported $0.95 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.81 by $0.14. The company had revenue of $575.76 million during the quarter, compared to analyst estimates of $584.30 million. Enovis had a negative net margin of 52.69% and a positive return on equity of 8.74%. The firm’s quarterly revenue was up 2.6% compared to the same quarter last year. During the same period in the previous year, the business earned $0.98 earnings per share. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, equities research analysts expect that Enovis Corporation will post 2.79 earnings per share for the current fiscal year.

Analyst Ratings Changes

ENOV has been the subject of a number of research reports. Needham & Company LLC upped their price objective on Enovis from $49.00 to $52.00 and gave the stock a “buy” rating in a report on Thursday, February 26th. Canaccord Genuity Group decreased their price objective on Enovis from $58.00 to $50.00 and set a “buy” rating on the stock in a report on Wednesday, December 17th. Zacks Research upgraded Enovis from a “hold” rating to a “strong-buy” rating in a research report on Wednesday. BTIG Research upped their target price on Enovis from $41.00 to $43.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. Finally, UBS Group reiterated a “buy” rating and set a $50.00 price target on shares of Enovis in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Enovis presently has an average rating of “Moderate Buy” and a consensus target price of $47.43.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ENOV. Rubric Capital Management LP purchased a new stake in Enovis during the 3rd quarter valued at about $83,435,000. Tributary Capital Management LLC grew its position in Enovis by 91.5% during the 3rd quarter. Tributary Capital Management LLC now owns 1,154,482 shares of the company’s stock worth $35,027,000 after acquiring an additional 551,613 shares during the last quarter. AQR Capital Management LLC increased its stake in Enovis by 682.6% in the 2nd quarter. AQR Capital Management LLC now owns 498,317 shares of the company’s stock worth $15,627,000 after purchasing an additional 434,646 shares during the period. Boston Partners increased its stake in Enovis by 42.4% in the 2nd quarter. Boston Partners now owns 1,382,724 shares of the company’s stock worth $43,352,000 after purchasing an additional 411,744 shares during the period. Finally, Geode Capital Management LLC lifted its position in Enovis by 43.8% in the second quarter. Geode Capital Management LLC now owns 1,342,481 shares of the company’s stock valued at $42,105,000 after purchasing an additional 408,608 shares during the last quarter. Hedge funds and other institutional investors own 98.45% of the company’s stock.

Enovis Company Profile

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.